Spruce Biosciences’ stock plummets in wake of PhIIb flop, biotech to cut staff
2024-03-14
临床2期临床结果临床失败
Spruce Biosciences’ tildacerfont failed a Phase IIb test in adults with congenital adrenal hyperplasia (CAH) due to compliance issues, crushing its stock $SPRB by as much as 75% premarket.
In the 96-patient CAHmelia-203 trial, the oral CRF1 receptor antagonist did not meet the primary endpoint of change in androstenedione (A4) levels at 12 weeks. The company said there was low compliance with the drug and standard of care glucocorticoid (GC) steroids, with only about half of patients noting they were at least 80% compliant.
Preview
来源: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。